Michael Gelband’s Cytek Biosciences CTKB Stock Holding History

Michael Gelband’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160K	Buy	+36,140	New	+$154K	﹤0.01%	1437
2025 Q4	–	Sell	-62,970	Closed	-$219K	–	1638
2025 Q3	$219K	Sell	62,970 -171,727	-73%	-$645K	﹤0.01%	1367
2025 Q2	$798K	Buy	+234,697	New	+$782K	0.01%	1027
2025 Q1	–	Sell	-77,536	Closed	-$503K	–	1555
2024 Q4	$503K	Sell	77,536 -41,706	-35%	-$248K	﹤0.01%	1153
2024 Q3	$661K	Buy	119,242 +82,208	+222%	+$466K	﹤0.01%	1102
2024 Q2	$207K	Buy	+37,034	New	+$222K	﹤0.01%	1387
2023 Q2	–	Sell	-119,770	Closed	-$1.1M	–	1918
2023 Q1	$1.1M	Buy	+119,770	New	+$1.29M	0.01%	1109
2022 Q2	–	Sell	-27,049	Closed	-$292K	–	2016
2022 Q1	$292K	Buy	+27,049	New	+$365K	﹤0.01%	1772

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's CTKB Position: Q2 2026 in Review

Michael Gelband opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 36,140 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #1437 among its holdings. This is a return to the name: Michael Gelband previously reported a position in CTKB as recently as Q3 2025.

Michael Gelband first reported a position in CTKB in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.1M in Q1 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Michael Gelband held 36,140 shares of Cytek Biosciences worth $160K as of Q2 2026.
Cytek Biosciences was a new Michael Gelband position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1437 holding.
Michael Gelband first reported a position in Cytek Biosciences in Q1 2022 and has held it in 8 quarters since.
Michael Gelband's Cytek Biosciences position peaked at $1.1M in Q1 2023.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.